Geode Capital Management LLC Has $2.65 Million Holdings in Agenus Inc. (NASDAQ:AGEN)

Geode Capital Management LLC increased its position in shares of Agenus Inc. (NASDAQ:AGEN) by 7.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 483,059 shares of the biotechnology company’s stock after buying an additional 32,016 shares during the period. Geode Capital Management LLC owned 2.06% of Agenus worth $2,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. bought a new position in shares of Agenus in the 2nd quarter valued at about $1,921,000. Blair William & Co. IL acquired a new stake in Agenus in the 2nd quarter valued at about $441,000. Point72 DIFC Ltd acquired a new position in Agenus during the second quarter worth approximately $51,000. Squarepoint Ops LLC acquired a new position in Agenus during the second quarter worth approximately $614,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Agenus in the second quarter valued at approximately $106,000. 61.46% of the stock is owned by institutional investors.

Agenus Trading Up 7.3 %

NASDAQ:AGEN opened at $3.55 on Wednesday. The stock has a 50 day simple moving average of $3.25 and a 200 day simple moving average of $5.87. The stock has a market cap of $83.28 million, a P/E ratio of -0.32 and a beta of 1.27. Agenus Inc. has a 1-year low of $2.50 and a 1-year high of $19.69.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Agenus has an average rating of “Hold” and a consensus price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.